RA Outcomes Improved in KURAMA Cohort - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

RA Outcomes Improved in KURAMA Cohort

Ten-year observational data showed lower disease activity and functional disability coinciding with broader use of biologic and targeted synthetic therapies.

  • By

  • Andrea Surnit

  • May 22, 2026

  • 4 min

Share

Objective:

To analyze the long-term outcomes of patients with rheumatoid arthritis (RA) in the KURAMA cohort over a 10-year period.

Key Findings:
  • Include detail about methotrexate use remaining above 60% throughout the study period.
Interpretation:

Remove unsupported conclusions regarding the sensitivity of the Disease Activity Score 28-C-reactive protein.

Limitations:
  • Explicitly mention the lack of generalizability due to the single-center nature of the study.
Conclusion:

Remove unsupported summary statements about the transition of therapeutic strategies.

Original Source(s)

RA Outcomes Improved in KURAMA Cohort

  • by Andrea Surnit

  • May 22, 2026

Related Content

Lung Disease Complicates RA Care

Patients with chronic lung disease had numerically lower remission rates and substantially more serious adverse events in a 5-year Japanese registry study of late-onset rheumatoid arthritis.

Rheumatoid arthritis tied to birth outcomes

Researchers examine pregnancy outcomes and factors associated with preterm delivery and fetal size.

Trial Exclusions May Skew RA Drug Comparisons

Nearly 40% of registry patients would have been excluded from phase 3 randomized controlled trials, with exclusion criteria distributed unevenly across drug classes.